Hematologic toxicity of sodium valproate

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 1, 2000, Pages 62-65

  Acharya, Suchitra ^a   Bussel, James B ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Acquired von willebrand disease; Bone marrow suppression; DDAVP; Hypofibrinogenemia; Thrombocytopenia; Valproate

Indexed keywords

VALPROIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; APLASTIC ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CYTOPENIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FATALITY; HUMAN; LABORATORY TEST; MEGALOCYTOSIS; MONOTHERAPY; MYELODYSPLASIA; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RECURRENT DISEASE; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

ANTICONVULSANTS; BONE MARROW; CHILD; HEMATOLOGIC DISEASES; HUMANS; VALPROIC ACID;

EID: 0034457590     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200001000-00012     Document Type: Article

References (31)

1. Ohtsuka Y, Amano R, Mizukawa M, et al. Treatment of intractable childhood epilepsy with high-dose valproate. Epilepsia 1992; 33: 158-64.
2. Murphy JV. Valproate monotherapy in children. Am J Med 1988; 84: 1A.
3. Dreiffus FE, Langer DH. Side effects of valproate. Am J Med 1988; (suppl A): 34-41.
4. Clancy RR. Valproate, an update: the challenge of modern pediatric seizure management. Curr Prob Ped 1990; 20(4): 167-233.
5. May R, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia 1993; 34(6): 1098-101.
6. Ganick DJ, Sunder T, Finley JL. Severe hematologic toxicity of valproic acid: a report of four patients. Am J Pediatr Hematol Oncol 1990; 12(1): 80-5.
7. Bottom KS, Adams DM, Mann KP, et al. Trilineage hematopoietic toxicity associated with valproic acid therapy. J Pediatr Hematol Oncol 1997; 19(1): 73-6.
8. MacDougall LG. Pure red cell aplasia associated with sodium valproate therapy. JAMA 1982; 247(1): 53-4.
9. Kawauchi K, Miyano T, Ikeda Y, et al. A report of a case with pure red cell aplasia induced by sodium valproate. Acta Pediatr Jpn 1989; 31: 615-9.
10. Barr RD, Copeland SA, Stockwell ML, et al. Valproic acid and immune thrombocytopenia. Arch Dis Child 1982; 57: 681-4.
11. Kishi T, Fujita N, Kawaguchi H, et al. Bone marrow suppression induced by high-dose valproic acid. Arch Dis Child 1994; 71: 153-5.
12. Sunder T, May RB. Valproic acid-induced macrocytosis. Epilepsia 1988; 5: 670.
13. Davis RB, Sunder TR, Barakat HA, et al. Valproate alters the membrane phospholipids of erythrocytes. Epilepsia 1991; 32(suppl 3): 11-2.
14. Jaeken J, Van Goethem C, Casear P, et al. Neutropenia during sodium valproate treatment [letter]. Arch Dis Child 1979; 54: 986-7.
15. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982; 23: 693-720.
16. Neophytides AN, Nutt JG, Lodish JR. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol 1979; 5(4): 389-90.
17. Delgado MR, Riela AR, Janith Mills PA-C, et al. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994; 9(3): 311-4.
18. von Voss H, Schulte-Berbuhl R, Gobel U. Side effects of sodium valproate (sodium di-N-propylacetate) on malonyldialdehyde production and other platelet function tests. Minerva Pediatr 1978; 30: 1397-1404.
19. Sandler RM, Emberson C, Roberts GE, et al. IgM platelet autoantibody due to sodium valproate. Br Med J 1978; 2: 1683-4.
20. Morris N, Barr RD, Pai KRM, et al. Valproic acid and thrombocytopenia. Can Med Assoc J 1981; 125: 63-4.
21. Dale BM, Purdie GH, Rischbieth RH. Fibrinogen depletion with sodium valproate. Lancet 1978; 1: 1316-7.
22. Kreuz W, Linde R, Funk M, et al. Valproate therapy induces von Willebrand disease type I. Epilepsia 1992; 33(1): 178-84.
23. Richardson SGN, Fletcher DJ, Jeavons PM, et al. Sodium valproate and platelet function. Br Med J 1976; 1: 221-2.
24. von Voss H, Petrich C, Schulz H-U, et al. Hemorrhagic diathesis and platelet dysfunction in children under treatment with sodium valproate. Epilepsia 1978b; 19: 113-4.
25. Kreuz W, Mentzer D, Becker S, et al. Haemate-P in children with von Willebrand’s disease. Hemostasis 1994; 24: 304-10.
26. Winter SL, Kriel RL, Novacheck TF, et al. Perioperative blood loss: the effect of valproate. Pediatr Neurol 1996; 15(1): 19-22.
27. Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 1994; 69: 173-80.
28. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991; 32(suppl 2): S9-12.
29. Sherbany AA, Rothman J, Jayabose S. Delayed-onset dose-related, valproate-induced thrombocytopenia. Neurology 1990; 40(suppl 1): 137.
30. Rajantie J, Kajosaari V, Ylitalo V. Fatal pancytopenia during high-dose valproate monotherapy. Eur J Pediatr 1992; 151: 619-20.
31. Watts RG, Emanuel PD, Zuckerman KS, Howard TH. Valproic acid-induced cytopenias: evidence for a dose-related suppression of hematopoiesis. J Pediatr 1990; 117: 495-9.